浦瑞生物浦瑞生物 合作、创新、共赢。
我们是一家专门从事纳米药物制剂和生物药物开发的高科技生物医药企业，由多名资深医药专家和Aldlab投资人共同组建，创始人在国内外的生物医药学术界和工业界具有丰富的从业经验。
详细介绍
PR-1 注射用多西他赛脂质体 Liposomal Docetaxel
PR-1 is a novel nanoparticle formulation of docetaxel (Taxotere), a drug widely used in the treatment of a variety of solid tumor types. The American Cancer Society estimates that 1.6 million new cases of cancer will be reported in the US in 2012, and that 577,000 people will die as a result of this disease. Cancer is the second most common cause of death after heart disease, accounting for nearly one in four deaths. Taxotere generated worldwide revenue of ~$2.7B (�2.1) in 2010. A unique opportunity exists for this novel formulation of docetaxel to capture significant market share based on its improved safety, tolerability and efficacy profile over docetaxel (Taxotere).
PR-2 双氯芬酸胶囊
PR-2 is a novel formulation of diclofenac prepared by nanoemulsion drug delivery system.Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) indicated for management of mild to moderate acute pain and osteoarthritis (OA) pain.
PR-3 环孢菌素
PR-3 is a novel ciclosporin nanoemulsion eye drops intended for the treatment of severe keratitis in adult patients with dry eye disease (DED).The active substance of PR-3 is ciclosporin, an immunosuppressant belonging to the therapeutic class of ophtalmologicals. Ciclosporin blocks the release of pro-inflammatory cytokines and exerts an anti-inflammatory effect in ocular surface cells.
PR-4 雌二醇透皮凝胶
PR-4(estradiol topical nanoemulsion) is designed to deliver estradiol to the blood circulation following topical application of an nanoemulsion. Estradiol is intended for the treatment of moderate to severe vasomotor symptoms associated with menopause.